Study for migraine

Who may participate

This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. 

You may not take part in this study if:

• You are younger than 18 years or you weigh less than or equal to 45 kg or you are outside of the limits for Body Mass Index (16 - 32 kg/m2).
• You have experienced a suicidal ideation in the past year or suicidal behaviour in the past 10 years. Your risk of experiencing a suicidal state of mind will be evaluated with the investigator or the PCRU staff before you may be included in the study as well as after taking the medication.

There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process. 
 

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium. 

The study will last for about 11 weeks. 

You will stay in the PCRU for 4 consecutive treatment periods with a total stay of 21 days and 20 nights in the PCRU. 

You will leave the facility after the last period. 

The follow-up phone call will take place approximately 28-35 days after the last administration of the study drug.

You will be screened within 28 days prior to the first dose of study intervention.

Throughout the study, staff will closely monitor your health status and collect data.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
 

See calendar